• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

NovaSight releases successful results of amblyopia treatment trial


The company’s digital treatment device was proven to be non-inferior to eye patch treatment in a randomly assigned controlled study.

NovaSight has released positive pivotal data from its multicenter, randomly assigned, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia, commonly known as "lazy eye."

The study, which randomly assigned 103 patients from the ages of 4 to 9, compared the improvement in visual outcomes achieved by CureSight digital treatment versus eye patching, considered the current gold-standard-of-care treatment.

According to the company, the study was one of the first in which digital device was shown to be non-inferior to eye patching for amblyopia treatment in children.

In addition to achieving the non-inferiority primary endpoint, NovaSight noted that the topline analyses from the pivotal study demonstrated that best corrected visual acuity (BCVA) improvement at week 16 was larger in the treatment group compared to the patching control group.

The company noted that a significant stereo acuity improvement was observed in both groups. No serious adverse events were observed in either treatment arms (CureSight or patching) and all non-serious adverse events were transient and self-limiting.

The study also evaluated adherence and patient satisfaction. The mean adherence to CureSight use during the study among subjects evaluated at the week 16 visit (N = 43) was 93%, as measured by the CureSight's eye tracking system. In addition, 93% of parents reported that they are likely or very likely to choose the CureSight digital treatment over patching.

According to the company, the clinical study was conducted in six medical centers, including Sheba Medical Center, which was ranked one of the top 10 best hospitals in the world by Newsweek, in 2021.

NovaSight CEO Ran Yam said in a news release that the company was pleased to have completed the CureSight study and further validate its safety and effectiveness as measured by visual acuity and stereoacuity improvement in comparison to patching and with a high safety profile and user satisfaction.

“Eye patching is effective when patients are compliant, however, patching is often associated with insufficient adherence due to the discomfort it brings to the patient and the social stigma that many children experience when wearing a patch," Yam said in a statement. “The success of the CureSight study is a critical step toward bringing this treatment for lazy eye to children around the world and to potentially modernizing the standard of care.”

According to the company, CureSight is a digital device that trains the visual system to use both eyes simultaneously, while the user watches any streamed video content through red-blue treatment glasses. Using sophisticated algorithms and eye-tracking technology, CureSight blurs the center of vision of the image that is shown to the strong eye using real-time image processing.

This encourages the brain to complete the image fine details from the amblyopic eye image and trains the two eyes to work as a team. The device is designed to be used at home, and it shares treatment reports with caregivers via a cloud portal.

“Innovative solutions that make amblyopia treatment easier for patients to access and clinicians to prescribe and evaluate effectiveness are welcome and increasingly necessary," said Michael Repka, MD, MBA, a professor of ophthalmology at Johns Hopkins University.

NovaSight has initiated a Series B financing round in addition to the $20 million the Israeli startup raised to date. Following on the recently granted CE mark approval for CureSight in Europe, completion of the CureSight pivotal trial represents a significant step forward to securing US FDA clearance.

With three unique CPT codes for the CureSight treatment already effective since January, NovaSight is in a position to take the next step soon with the submission of its application for 510(k) clearance of the device.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
© 2024 MJH Life Sciences

All rights reserved.